These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
223 related articles for article (PubMed ID: 19782109)
1. Constructing target product profiles (TPPs) to help vaccines overcome post-approval obstacles. Lee BY; Burke DS Vaccine; 2010 Apr; 28(16):2806-9. PubMed ID: 19782109 [TBL] [Abstract][Full Text] [Related]
2. Post-marketing safety monitoring of a new group B meningococcal vaccine in New Zealand, 2004-2006. McNicholas A; Galloway Y; Stehr-Green P; Reid S; Radke S; Sexton K; Kieft C; Macdonald C; Neutze J; Drake R; Isaac D; O'Donnell M; Tatley M; Oster P; O'Hallahan J Hum Vaccin; 2007; 3(5):196-204. PubMed ID: 17660718 [TBL] [Abstract][Full Text] [Related]
3. Assessment of Communication Strategies for Mitigating COVID-19 Vaccine-Specific Hesitancy in Canada. Merkley E; Loewen PJ JAMA Netw Open; 2021 Sep; 4(9):e2126635. PubMed ID: 34591105 [TBL] [Abstract][Full Text] [Related]
4. How vaccine safety is monitored before and after licensure. Macartney KK; Offit PA Pediatr Ann; 2001 Jul; 30(7):392-9. PubMed ID: 11469170 [No Abstract] [Full Text] [Related]
5. Vaccine Safety. Morris L; Swofford S Prim Care; 2020 Sep; 47(3):431-441. PubMed ID: 32718441 [TBL] [Abstract][Full Text] [Related]
6. Pricing of new vaccines. Lee BY; McGlone SM Hum Vaccin; 2010 Aug; 6(8):619-26. PubMed ID: 20861678 [TBL] [Abstract][Full Text] [Related]
7. Postmarketing Safety of Vaccines Approved by the U.S. Food and Drug Administration : A Cohort Study. Tau N; Yahav D; Shepshelovich D Ann Intern Med; 2020 Sep; 173(6):445-449. PubMed ID: 32716700 [TBL] [Abstract][Full Text] [Related]
8. Synopsis of a workshop on post-marketing surveillance of vaccine-associated adverse events. Can Dis Wkly Rep; 1991 May; 17(19):97-8. PubMed ID: 1677614 [No Abstract] [Full Text] [Related]
9. An introduction to analytical methods for the postmarketing surveillance of veterinary vaccines. Siev D Adv Vet Med; 1999; 41():749-74. PubMed ID: 9890058 [TBL] [Abstract][Full Text] [Related]
10. Vaccine safety. Reid S N Z Med J; 2020 Feb; 133(1510):83-87. PubMed ID: 32078604 [TBL] [Abstract][Full Text] [Related]
11. [Develop the active surveillance system for vaccine safety in China]. Cai T; Zhan SY Zhonghua Yu Fang Yi Xue Za Zhi; 2019 Jul; 53(7):664-667. PubMed ID: 31288335 [TBL] [Abstract][Full Text] [Related]
12. Ethical considerations in post-market-approval monitoring and regulation of vaccines. Thompson A; Komparic A; Smith MJ Vaccine; 2014 Dec; 32(52):7171-4. PubMed ID: 25454882 [TBL] [Abstract][Full Text] [Related]
13. Perspectives on the future of postmarket vaccine safety surveillance and evaluation. Ball R Expert Rev Vaccines; 2014 Apr; 13(4):455-62. PubMed ID: 24606417 [TBL] [Abstract][Full Text] [Related]